IDT Biologika in the news

SK bioscience narrowed its Q2 operating loss by 58% due to improved performance at its German subsidiary IDT Biologika, offsetting R&D and expansion costs.

SK Bioscience's Q2 operating loss significantly narrowed, primarily due to the improved performance of its German unit, IDT Biologika, despite a wider first-half loss impacted by relocation and R&D costs.

SK bioscience halved its Q2 operating loss due to improved performance at its German subsidiary IDT Biologika, offsetting R&D and expansion costs.

SK Bioscience halved its Q2 operating loss thanks to the recovery of its German subsidiary, IDT Biologika, and plans to boost its CDMO business and vaccine expansion.

SK Bioscience expects accelerated earnings recovery in 2024 from increased vaccine sales and expanding CDMO orders, despite anticipated operating losses due to ongoing investments.

IDT Biologika plans capacity expansion and M&A to reach 500 million euros in revenue by 2028-2029, capitalizing on synergies with SK Bioscience.

IDT Biologika is expanding its global biopharmaceutical manufacturing presence through international events and targeting $294.86 million in revenue for 2025.

Revenue grew by 9% due to IDT Biologika's performance and vaccine sales, despite a widened operating loss from infrastructure and R&D costs.

SK Bioscience acquired IDT Biologika for $244 million to boost vaccine production and expand globally.

SK Bioscience is expanding its vaccine development and manufacturing capabilities through the acquisition of Germany-based IDT Biologika for $244 million.

SK bioscience formed a partnership with IDT Biologika to integrate and expand vaccine manufacturing, combining drug substance and drug product expertise for a broader end-to-end offering.

SK Bioscience and IDT Biologika collaborate on manufacturing MSD’s Ebola vaccine and partner on influenza vaccine development to enhance pandemic preparedness.

SK bioscience and IDT Biologika partnered with MSD to develop a more stable, accessible Ebola vaccine, enhancing global infectious disease response.

SK bioscience and IDT Biologika are collaborating on drug product development for MSD's Zaire Ebola vaccine, funded by CEPI, aiming to improve manufacturing and supply stability.

SK bioscience and IDT Biologika collaborate to enhance and produce MSD’s Zaire Ebola vaccine and co-develop next-gen influenza vaccines under CEPI and European health initiatives.

SK Bioscience and IDT Biologika partnered with MSD to develop and manufacture a second-generation Ebola vaccine.

SK bioscience and IDT Biologika teamed up to manufacture MSD's Ebola vaccine, improving production efficiency and vaccine stability.

SK bioscience partners with IDT Biologika to develop and manufacture an improved Ebola vaccine addressing manufacturing and distribution challenges.

In 2025, SK bioscience's revenue jumped 144% aided by IDT Biologika’s profitability and strong vaccine sales, while operating losses narrowed amid heavy R&D investment.

SK bioscience, IDT Biologika, and Vaxxas won EU funding to develop a patch-type flu vaccine using needle-free technology, with IDT leading European operations and manufacturing.